Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1013 participants
OBSERVATIONAL
2013-11-30
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Finnish AntiCoagulation in Atrial Fibrillation (FinACAF)
NCT04645537
Atrial Fibrillation Burden and Long-term Risk of Thromboembolic Complications- the FinCV-4 Study
NCT04001205
FINnish CardioVersion Study II
NCT02850679
Management of Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting
NCT00596570
ImplemeNtation oF demOnstration pRoject for Health systeMs: Atrial Fibrillation (INFORM-AF) Part 1
NCT02569528
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Working hypothesis is that the treatment of AF has improved since the introduction of new antiarrhythmic drugs and anticoagulants. However, the investigators also expect to find out that there are geographical differences in the use of these agents. The expect outcome is that the investigators will identify these differences and be able to better homogenize the treatment of AF in different parts of the country and different levels of the health care system.
The study data will be obtained in the form of a cross-section sampling over two weeks. All patients with ECG-diagnosed AF who attend emergency clinics for examination or treatment of arrhythmia or other cardiac diseases during the study period will be included. The investigators estimate the number of patients will be about 1000. Aside from background information, risk data (e.g. CHA2DS2VASc), symptoms (EHRA classification), medication, examinations and the choice of treatment, the only data recorded about each patient with AF will be date of birth and gender. The patients will be divided into four groups according to type of AF: 1. New onset AF, 2. Paroxysmal AF, 3. Persistent AF, 4. Permanent AF. The data will be obtained by the local study doctor using online, protected data collection program. The data will be stored on a secured server, which can be accessed for data entry by the investigators at the study centers. The database is not a personal data register, as identity codes will not be stored at any point and individual patients cannot be identified later through the database. Only the investigator group will have the rights to use the database.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with AF in the ER
All patients with ECG-diagnosed AF who attend emergency clinics for examination or treatment of arrhythmia or other cardiac diseases during the study period will be included.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Helsinki University Central Hospital
OTHER
Kuopio University Hospital
OTHER
Oulu University Hospital
OTHER
Tampere University Hospital
OTHER
Turku University Hospital
OTHER_GOV
Finnish Cardiac Society
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pekka Raatikainen, MD, PhD
Role: STUDY_CHAIR
Heart Center Tampere Univerisity Hospital
Juha Hartikainen, MD
Role: PRINCIPAL_INVESTIGATOR
Kuopio University Hospital
Timo Lauri, MD
Role: PRINCIPAL_INVESTIGATOR
Oulu University Hospital
Mika Lehto, MD
Role: PRINCIPAL_INVESTIGATOR
Helsinki University Central Hospital
Markku Mäkijärvi, MD
Role: PRINCIPAL_INVESTIGATOR
Helsinki University Central Hospital
Juha Lund, MD
Role: PRINCIPAL_INVESTIGATOR
Turku University Hospital
Heikki Mäkynen, MD
Role: PRINCIPAL_INVESTIGATOR
Heart Center Tampere University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Helsinki University Central Hospital
Helsinki, , Finland
Kuopio University Hospital
Kuopio, , Finland
Oulu University Hospital
Oulu, , Finland
Tampere University Hospital
Tampere, , Finland
Turku University Hospital
Turku, , Finland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Penttila T, Makynen H, Hartikainen J, Hyppola H, Lauri T, Lehto M, Lund J, Raatikainen MJP; FinFib2 investigators. Antiarrhythmic drug therapy among patients presenting to emergency department with symptomatic atrial fibrillation - a prospective nationwide cohort. Scand J Trauma Resusc Emerg Med. 2017 Aug 15;25(1):81. doi: 10.1186/s13049-017-0424-7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R13044
Identifier Type: OTHER
Identifier Source: secondary_id
FCS-2013-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.